Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer.
Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.
Amivantamab-vmjw plus carboplatin and pemetrexed, administered with or without lazertinib, significantly improved progression-free survival vs chemotherapy alone in patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 19 deletions or L858R substitutions after progression on or after osimertinib.
Balversa has been submitted to the FDA for approval to treat patients with locally advanced or metastatic urothelial carcinoma.
News Release Media Contacts: Suzanne Frost Phone: +1 416-317-0304 Ania DiAntonio ...